IDIENCE CO., LTD.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.idience.com
Clinical Trials
4
Active:0
Completed:3
Trial Phases
1 Phases
Phase 1:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (100.0%)Food Effect Study of IDX-1197 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Male
- Interventions
- Drug: IDX-1197(After a meal)Drug: IDX-1197(fasting)
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- Idience Co., Ltd.
- Target Recruit Count
- 37
- Registration Number
- NCT05202912
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer
Phase 1
Recruiting
- Conditions
- Gastric Cancer
- Interventions
- Drug: IDX-1197+XELOXDrug: IDX-1197+Irinotecan
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- Idience Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT04725994
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Astera Cancer Care, East Brunswick, New Jersey, United States
🇰🇷Dong-A University Hospital, Busan, Korea, Republic of
Basket Trial of IDX-1197, a PARP Inhibitor, in Patients With HRR Mutated Solid Tumors (VASTUS)
Phase 1
Completed
- Conditions
- Solid TumorsHomologous Recombination Repair Gene MutationHomologous Recombination Deficiency
- Interventions
- First Posted Date
- 2019-11-22
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- Idience Co., Ltd.
- Target Recruit Count
- 310
- Registration Number
- NCT04174716
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of
🇰🇷National Cancer Centre, Goyang, Gyeongggi-do, Korea, Republic of
🇰🇷Ajou University Hospital, Suwon, Gyeonggi-do, Korea, Republic of
Study to Assess the Safety & Tolerability of NOV140101(IDX-1197) in Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: NOV140101 (IDX-1197)
- First Posted Date
- 2017-10-23
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Idience Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT03317743
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Songpa-gu, Korea, Republic of
News
No news found